Arterial hypertension, or high blood pressure, arises from dysregulated vascular tone, altered endothelial function, sympathetic overactivity, and rarefaction of capillary beds — pathophysiological mechanisms studied across essential and secondary forms.
Arterial hypertension, or high blood pressure, arises from dysregulated vascular tone, altered endothelial function, sympathetic overactivity, and rarefaction of capillary beds — pathophysiological mechanisms studied across essential and secondary forms. Stem-cell research investigates whether placental mesenchymal stem cells and exosome preparations can restore endothelial homeostasis, promote vascular regeneration, suppress renin-angiotensin-aldosterone axis overactivity, and enhance nitric-oxide bioavailability. With 35 registered trials and 4 currently recruiting, the therapeutic rationale targets restoration of vascular biology rather than symptomatic blood-pressure control. Early clinical data suggest potential for reducing office and ambulatory blood pressure, improving microvascular function, and reducing left-ventricular hypertrophy when administered as adjuncts to standard antihypertensive therapy.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €5,000–€25,000 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 35 · 4 recruiting now |
For the clinic's own description, see how Stem Plus describes its Arterial Hypertension programme ↗.
Clinical hypertension trials show preliminary promise but remain modest in sample size and follow-up duration. Four actively recruiting trials indicate continuing clinical interest. Published studies document reductions in systolic and diastolic blood pressure (5–15 mmHg average decreases) and improvements in vascular stiffness markers following MSC or exosome infusion. Flow-mediated dilation (endothelial function) showed improvement in responsive cohorts. Left-ventricular mass index decreased in some long-term follow-up assessments. However, heterogeneous patient populations, variable blood-pressure definitions, and concurrent antihypertensive medication use limit interpretation. Mechanism studies suggest paracrine effects driving benefit, but direct in-vivo confirmation remains sparse. Durability of blood-pressure reduction beyond 12 months is incompletely characterised.
Depending on assessment, a Arterial Hypertension protocol may draw on:
Arterial hypertension stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source and formulation. Exosome-based therapies, when offered, may cost similarly to MSCs or slightly higher due to manufacturing complexity. Single-infusion protocols are more common in hypertension than multi-cycle regimens, potentially reducing total expense compared to other conditions. Placental MSCs are favoured for cost-efficiency and cardiovascular safety profile. Home-based blood-pressure monitoring adds minimal cost but is essential for outcome assessment. European hospital-affiliated programmes typically charge €3,500–5,000; private cardiovascular clinics may exceed €6,500. Insurance rarely covers experimental therapy, necessitating out-of-pocket payment.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Arterial Hypertension cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Arterial Hypertension.
Full Arterial Hypertension FAQ → · Arterial Hypertension cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם